Triasima Portfolio Management inc. purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 3,695 shares of the biopharmaceutical company's stock, valued at approximately $414,000.
Other institutional investors have also recently made changes to their positions in the company. Smallwood Wealth Investment Management LLC purchased a new position in shares of Gilead Sciences during the first quarter valued at $25,000. Goodman Advisory Group LLC bought a new stake in Gilead Sciences during the first quarter valued at about $29,000. Annis Gardner Whiting Capital Advisors LLC boosted its position in Gilead Sciences by 158.8% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 216 shares in the last quarter. Core Alternative Capital boosted its holdings in Gilead Sciences by 370.8% in the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 241 shares in the last quarter. Finally, Lee Danner & Bass Inc. acquired a new stake in Gilead Sciences in the fourth quarter worth about $41,000. Hedge funds and other institutional investors own 83.67% of the company's stock.
Gilead Sciences Stock Up 0.0%
Shares of GILD traded up $0.04 during mid-day trading on Friday, reaching $108.84. The company's stock had a trading volume of 1,830,842 shares, compared to its average volume of 7,647,666. Gilead Sciences, Inc. has a 12-month low of $70.78 and a 12-month high of $119.96. The stock has a market cap of $135.38 billion, a PE ratio of 22.94, a price-to-earnings-growth ratio of 0.71 and a beta of 0.29. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. The company's 50 day moving average is $108.58 and its 200 day moving average is $105.06.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The business's revenue for the quarter was down .3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.32) EPS. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.
Gilead Sciences Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were given a $0.79 dividend. The ex-dividend date was Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.90%. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.
Wall Street Analyst Weigh In
A number of research firms have recently commented on GILD. JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Morgan Stanley boosted their price objective on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Cantor Fitzgerald initiated coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective on the stock. Oppenheimer lowered their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Nine equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $111.38.
Get Our Latest Stock Analysis on GILD
Insider Transactions at Gilead Sciences
In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction that occurred on Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total transaction of $333,090.00. Following the completion of the sale, the insider directly owned 117,168 shares of the company's stock, valued at approximately $13,009,163.04. This trade represents a 2.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, June 30th. The shares were sold at an average price of $110.45, for a total value of $1,104,500.00. Following the completion of the transaction, the chief executive officer directly owned 615,725 shares of the company's stock, valued at $68,006,826.25. The trade was a 1.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 72,000 shares of company stock valued at $7,844,775 in the last 90 days. Company insiders own 0.27% of the company's stock.
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
